AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.

We provide aggregated data on dividend stocks. AbbVie has been named a Top Socially ... Below is a long-term dividend history chart for ABBV, which the DividendRank report stressed as being ...

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Positive Phase 2 data for emraclidine, expected by the end of 2024, could potentially unlock a multi-billion dollar market opportunity. AbbVie has been proactive in strengthening its portfolio and ...

Full Year 2024 Results Key Financial Results Revenue: US$56.3b (up 3.7% from FY 2023). Net ...

AbbVie has reported new phase 3 data for its schizophrenia and bipolar disorder therapy Vraylar in treatment-resistant depression, as it waits for a decision by the FDA on the new indication.

AbbVie holds a strong portfolio of marketed and ... Imbruvica's strong clinical data in several forms of blood cancer led to peak sales above $5 billion, but increasing competition has led to ...